Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.vTv Therapeutics has enrolled the first patients in its Phase 2 LOGRA (aLlosteric Oral Glp1 Receptor Agonist) study, a randomized, double-blind, placebo-controlled, parallel group trial of TTP273.
Subscribe to our email newsletter
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential.
The previous Phase 1b trial of TTP273 demonstrated robust effects on postprandial and fasting glucose. All doses of TTP273 were safe and well tolerated with no serious adverse events or evidence of gastrointestinal side effects compared to placebo.
vTv President and CEO Steve Holcombe SAID: "Earlier studies of this compound showed that TTP273 has the potential to provide enhanced glycemic control and weight loss without the burden of injections or gastrointestinal side effects seen with GLP-1 biologic agents.
"TTP273 is just one of two diabetes treatments in our pipeline reading out this year with our best-in-class orally administered Glucokinase Activator, TTP399, expected to report Phase 2 results in mid-2016."
The LOGRA study is assessing the safety and efficacy of TTP273 in Type 2 diabetic patients on stable doses of metformin. The study’s primary endpoint is change in baseline in HbA1c at 3 months, with secondary endpoints including body weight, plasma glucose, lipids insulin, lactate, C-peptide, glucagon and GLP. The Company anticipates enrolling 156 patients at 26 clinical trial sites throughout the United States. Topline results are expected at the end of 2016.